Cancer Immunoediting in Malignant Glioma

被引：69

作者：

Dunn, Gavin P. ^{[1
]}

Fecci, Peter E. ^{[1
]}

Curry, William T. ^{[1
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Pappas Ctr Neurooncol,Sch Med, Boston, MA 02114 USA

来源：

NEUROSURGERY | 2012年 / 71卷 / 02期

关键词：

Cancer immunoediting; Elimination; Equilibrium; Glioma; Immunotherapy; Tumor escape; REGULATORY T-CELLS; GROWTH-FACTOR-RECEPTOR; TUMOR-INFILTRATING LYMPHOCYTES; PRIMARY INTRACRANIAL TUMORS; KIDNEY-TRANSPLANT RECIPIENTS; HUMAN-LEUKOCYTE ANTIGEN; DEEP CERVICAL LYMPH; BLOOD-BRAIN-BARRIER; TGF-BETA; GLIOBLASTOMA-MULTIFORME;

D O I：

10.1227/NEU.0b013e31824f840d

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Significant work from many laboratories over the last decade in the study of cancer immunology has resulted in the development of the cancer immunoediting hypothesis. This contemporary framework of the naturally arising immune system-tumor interaction is thought to comprise 3 phases: elimination, wherein immunity subserves an extrinsic tumor suppressor function and destroys nascent tumor cells; equilibrium, wherein tumor cells are constrained in a period of latency under immune control; and escape, wherein tumor cells outpace immunity and progress clinically. In this review, we address in detail the relevance of the cancer immunoediting concept to neurosurgeons and neuro-oncologists treating and studying malignant glioma by exploring the de novo immune response to these tumors, how these tumors may persist in vivo, the mechanisms by which these cells may escape/attenuate immunity, and ultimately how this concept may influence our immunotherapeutic approaches.

引用

页码：201 / 222

页数：22

共 322 条

[1] Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance [J].